Dynamic Responsiveness of Insulin Secretory Parameters To Sitagliptin and Glimeperide Administration in Type 2 DM

NAUnknownINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

June 30, 2015

Primary Completion Date

December 31, 2015

Study Completion Date

December 31, 2015

Conditions
Type 2 Diabetes
Interventions
DRUG

Glimepiride

Glimepiride 2mg qam

DRUG

Sitagliptin

Sitagliptin 100mg qam

DRUG

Metformin

Metformin as prescribed

All Listed Sponsors
collaborator

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

NIH

collaborator

Juvenile Diabetes Research Foundation

OTHER

collaborator

Amylin Pharmaceuticals, LLC.

INDUSTRY

collaborator

Eli Lilly and Company

INDUSTRY

collaborator

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

INDUSTRY

collaborator

Merck Sharp & Dohme LLC

INDUSTRY

collaborator

Novartis

INDUSTRY

collaborator

Pfizer

INDUSTRY

collaborator

Takeda

INDUSTRY

lead

Foundation for the National Institutes of Health

OTHER